Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-14

Clinical Trial Update: Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men [Phase 3]

View source ↗

Summary

Phase 3 trial of oral testosterone undecanoate for male hypogonadism completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oral testosterone undecanoate (testosterone undecanoate)

Snippet

Sponsor: Clarus Therapeutics, Inc. | Conditions: Male Hypogonadism | Phase 3 | Status: COMPLETED | Results posted: 2018-08-14